Researcher at Harvard Medical School develops AI-driven molecule targeting tumor mitochondria defects to destroy cancer ...

Colorectal cancer (CRC) arises from genetic and epigenetic alterations, including histone modifications. Unlike genetic changes, epigenetic ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in ...

The FDA has approved relacorilant (Lifyorli, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal ...

A new mass spectrometry imaging system achieves 800 nm resolution. The technology enables single-cell analysis of lipid ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed ...

Scientists have discovered that losing a key protein in small cell lung cancer triggers inflammation that actually helps ...

Inhibrx Biosciences is a high-risk, catalyst-driven biotech, with valuation hinging on the clinical success of ozekibart and ...

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, ...

A newly published study reports that APC-deficient cancer cells may depend on a single metabolic enzyme for survival, ...

Australian Manuka honey producer Biosota Organics is supporting women's health through its participation in the Mater Chicks ...

Absci Corporation downgraded to Hold as ABS-101 stalls and focus shifts to ABS-201; cash runway to H1 2028, but risks persist ...